AKTX
Price
$1.80
Change
-$0.06 (-3.23%)
Updated
Mar 27, 6:59 PM EST
CANF
Price
$2.20
Change
-$0.03 (-1.35%)
Updated
Mar 27, 6:59 PM EST
Ad is loading...

Compare predictions AKTX vs CANF

Header iconAKTX vs CANF Comparison
Open Charts AKTX vs CANFBanner chart's image
Akari Therapeutics
Price$1.80
Change-$0.06 (-3.23%)
Volume$25.81K
CapitalizationN/A
Can-Fite BioPharma
Price$2.20
Change-$0.03 (-1.35%)
Volume$4.34K
CapitalizationN/A
View a ticker or compare two or three
AKTX vs CANF Comparison Chart

Loading...

CANFDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
AKTX vs. CANF commentary
Mar 28, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKTX is a Hold and CANF is a StrongBuy.

COMPARISON
Comparison
Mar 28, 2024
Stock price -- (AKTX: $1.86 vs. CANF: $2.26)
Brand notoriety: AKTX and CANF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKTX: 339% vs. CANF: 54%
Market capitalization -- AKTX: $10.52M vs. CANF: $13.94M
AKTX [@Biotechnology] is valued at $10.52M. CANF’s [@Biotechnology] market capitalization is $13.94M. The market cap for tickers in the [@Biotechnology] industry ranges from $576.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.64B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKTX’s FA Score shows that 1 FA rating(s) are green whileCANF’s FA Score has 0 green FA rating(s).

  • AKTX’s FA Score: 1 green, 4 red.
  • CANF’s FA Score: 0 green, 5 red.
According to our system of comparison, CANF is a better buy in the long-term than AKTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CANF’s TA Score shows that 6 TA indicator(s) are bullish.

  • CANF’s TA Score: 6 bullish, 4 bearish.

Price Growth

AKTX (@Biotechnology) experienced а -2.09% price change this week, while CANF (@Biotechnology) price change was +1.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.41%. For the same industry, the average monthly price growth was +5.97%, and the average quarterly price growth was +87.01%.

Reported Earning Dates

AKTX is expected to report earnings on Dec 01, 2023.

CANF is expected to report earnings on Jun 01, 2023.

Industries' Descriptions

@Biotechnology (+4.41% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for AKTX with price predictions.
OPEN
A.I.dvisor published
a Summary for CANF with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
CANF($13.9M) has a higher market cap than AKTX($10.5M). CANF YTD gains are higher at: 2.727 vs. AKTX (-40.385). CANF has higher annual earnings (EBITDA): -10.14M vs. AKTX (-23.08M). CANF has more cash in the bank: 9.62M vs. AKTX (8.15M). CANF has less debt than AKTX: CANF (66K) vs AKTX (3.03M). CANF has higher revenues than AKTX: CANF (793K) vs AKTX (0).
AKTXCANFAKTX / CANF
Capitalization10.5M13.9M76%
EBITDA-23.08M-10.14M228%
Gain YTD-40.3852.727-1,481%
P/E RatioN/AN/A-
Revenue0793K-
Total Cash8.15M9.62M85%
Total Debt3.03M66K4,592%
FUNDAMENTALS RATINGS
AKTX vs CANF: Fundamental Ratings
AKTX
CANF
OUTLOOK RATING
1..100
5072
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
36
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
9058
P/E GROWTH RATING
1..100
11100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CANF's Valuation (36) in the Biotechnology industry is somewhat better than the same rating for AKTX (84) in the Pharmaceuticals Major industry. This means that CANF’s stock grew somewhat faster than AKTX’s over the last 12 months.

CANF's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AKTX (100) in the Pharmaceuticals Major industry. This means that CANF’s stock grew similarly to AKTX’s over the last 12 months.

CANF's SMR Rating (99) in the Biotechnology industry is in the same range as AKTX (100) in the Pharmaceuticals Major industry. This means that CANF’s stock grew similarly to AKTX’s over the last 12 months.

CANF's Price Growth Rating (58) in the Biotechnology industry is in the same range as AKTX (90) in the Pharmaceuticals Major industry. This means that CANF’s stock grew similarly to AKTX’s over the last 12 months.

AKTX's P/E Growth Rating (11) in the Pharmaceuticals Major industry is significantly better than the same rating for CANF (100) in the Biotechnology industry. This means that AKTX’s stock grew significantly faster than CANF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CANF
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
79%
Momentum
ODDS (%)
Bullish Trend 1 day ago
84%
MACD
ODDS (%)
Bullish Trend 1 day ago
72%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 18 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
76%
Aroon
ODDS (%)
Bullish Trend 1 day ago
80%
View a ticker or compare two or three
Ad is loading...
CANFDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
UPXI0.620.03
+5.53%
Upexi
PMTS16.750.62
+3.84%
CPI Card Group
IRDM26.300.71
+2.77%
Iridium Communications
RGR46.230.24
+0.52%
Sturm Ruger & Company
UMC7.980.03
+0.38%
United Microelectronic Corp

AKTX and

Correlation & Price change

A.I.dvisor tells us that AKTX and DSGN have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AKTX and DSGN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKTX
1D Price
Change %
AKTX100%
-1.33%
DSGN - AKTX
30%
Poorly correlated
+9.24%
GLTO - AKTX
27%
Poorly correlated
+3.38%
CANF - AKTX
22%
Poorly correlated
+3.67%
EVGN - AKTX
21%
Poorly correlated
+0.70%
FBIOP - AKTX
21%
Poorly correlated
+1.76%
More

CANF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CANF has been loosely correlated with ALDX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CANF jumps, then ALDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CANF
1D Price
Change %
CANF100%
+3.67%
ALDX - CANF
46%
Loosely correlated
+5.82%
TPST - CANF
27%
Poorly correlated
-0.27%
ORMP - CANF
26%
Poorly correlated
+4.41%
ARWR - CANF
25%
Poorly correlated
+3.12%
VIR - CANF
25%
Poorly correlated
+1.30%
More